GO
Loading...

FDA

More

  • Dendreon's Provenge Trial: Big Step On Bumpy Road Tuesday, 23 Oct 2007 | 2:58 PM ET

    It isn't moving the stock, but Dendreon this morning announced that it has signed up all of the patients for the big clinical trial that could lead to its prostate cancer drug, Provenge, winning Food and Drug Administration approval. The completion of enrollment was not unexpected, so that's why people aren't trading on the news.

  • Biogen Idec Earnings A 'Huge Swing and a Miss' Tuesday, 23 Oct 2007 | 12:13 PM ET

    Biotech giant Biogen Idec posted some disappointing third-quarter results, falling short of Wall Street expectations across the board. Does it matter, since the company has announced it's up for sale? Biotech analyst Christopher Raymond of Robert W. Baird thinks it does.

  • New Regulations? Food Industry Unlikely to Be Fazed Friday, 19 Oct 2007 | 2:29 PM ET

    Tighter food regulations under consideration could benefit consumers and companies alike, as Congress looks to help the industry through a crisis in confidence driven by a spate of high-profile recalls.

  • Impotence Drugs to Add Warning About Hearing Loss Thursday, 18 Oct 2007 | 5:13 PM ET
    Pfizer's Viagra

    U.S. regulators said warnings about the risk of sudden hearing loss linked to popular drugs for impotence, including Viagra, Cialis and Levitra, would be added to the drugs' labels.

  • Amylin, Eli Lilly Shares Slip On Diabetes Drug Worries Tuesday, 16 Oct 2007 | 1:52 PM ET

    The U.S. Food and Drug Administration said it had reviewed 30 reports of pancreatitis in patients taking Byetta, known generically as exenatide.

  • Merck Wins FDA Approval for AIDS Drug Friday, 12 Oct 2007 | 5:09 PM ET

    U.S. regulators approved a new AIDS treatment made by Merck, the first in a new class of drugs aimed at preventing replication of the virus, Merck said on Friday.

  • Glaxo Buys into Synta, Investors Sell Wednesday, 10 Oct 2007 | 1:08 PM ET

    Melanoma -- a type of skin cancer -- is the most common form of cancer. It can spread very quickly and the prognosis often is not good. The American Cancer Society estimates that nearly 60,000 new cases of melanoma will be diagnosed this year and more than 8,000 patients will die. You can find out more about it on the ACS's website.

  • Supreme Court Hears Landmark Investor Suit Tuesday, 9 Oct 2007 | 10:25 AM ET

    On Oct. 9, the U.S. Supreme Court will hear a case that some say may open the flood gates to a tidal wave of investor lawsuits. Legal experts joined CNBC to debate both sides of the issue.

  • Texas Oilman Pleads Guilty in Oil-for-Food Scandal Monday, 1 Oct 2007 | 11:24 AM ET
    Oscar Wyatt

    Texas oilman Oscar Wyatt pleaded guilty Monday to conspiracy to commit wire fraud, one of five counts against him for his role in the U.N. oil-for-food scandal.

  • Jets Fan Sues Patriots for $184 Million Sunday, 30 Sep 2007 | 12:51 PM ET

    A New York Jets season-ticket holder filed a class-action lawsuit Friday against the New England Patriots and coach Bill Belichick for "deceiving customers."

  • Dendreon's Provenge: The Latest On Cancer Drug Friday, 28 Sep 2007 | 9:34 AM ET

    Everyone's favorite biotech--investors seem to either love it or hate it--was one of the presenters this morning at the UBS Global Life Sciences Conference in New York City. CEO Dr. Mitchell Gold once again did the honors. Generally speaking, biotech investors focus on milestones or key events in drug development.

  • Eli Lilly Receives New FDA Approval For Evista Friday, 14 Sep 2007 | 8:25 AM ET

    Drug developer Eli Lilly said Friday the Food and Drug Administration approved its osteoporosis drug Evista for use in reducing the risk of invasive breast cancer.

  • Medicare Urged to Reimburse More for Anemia Drugs Tuesday, 11 Sep 2007 | 12:36 PM ET

    Is the Senate coming to the rescue of patients, investors or both? That's the question being raised after the passage of a non-binding resolution telling Medicare to "immediately reconsider" its new policy to cut anemia drug use and reimbursement. Analysts are stunned by the move.

  • FDA Meetings And Latest On Biotech Front Tuesday, 11 Sep 2007 | 10:59 AM ET

    So, I thought I'd be spending today monitoring the webcast of the FDA Advisory Committees that are meeting to decide whether doctors should use less of the anemia drugs from Amgen and Johnson & Johnson to treat kidney dialysis patients.

  • Stocks Get a Lift, Street on Fed Watch Tuesday, 11 Sep 2007 | 8:53 AM ET

    Wall Street is counting down to next week's Fed meeting and not much else is influencing trading. Stocks are readying for a higher opening as investors wait for a speech from Fed Chairman Ben Bernanke later this morning and watch the action at OPEC.

  • FDA Warns on Boston Scientific Aortic Stent Trial Monday, 10 Sep 2007 | 6:40 AM ET

    U.S. health regulators charged Boston Scientific with inadequate record-keeping and reporting following the deaths of five patients implanted with an experimental device to treat a dangerous ballooning of the body's main artery.

  • Amylin's Byetta LAR: Wait Is On For Results Thursday, 6 Sep 2007 | 4:08 PM ET

    An update from the NewsMakers in Biotech conference in NYC on an item of intense interest. Amylin Pharmaceuticals just held a well-attended PowerPoint presentation followed by a very cramped breakout session. And pretty much the only thing investors and analysts wanted to talk about is Byetta LAR (long-acting release).

  • Merck Wins Reversal of Vioxx Class-Action Status Thursday, 6 Sep 2007 | 12:27 PM ET

    Merck said Thursday the New Jersey Supreme Court has reversed a lower court ruling that had granted nationwide class-action status to insurers seeking reimbursement for past spending on Vioxx, the drugmaker's withdrawn arthritis treatment.

  • Merck's AIDS Drug Gets FDA Staff Support Friday, 31 Aug 2007 | 9:45 AM ET

    Benefits of an experimental AIDS drug developed by Merck & Co appear to outweigh risks, according to U.S. Food and Drug Administration staff documents released Friday ahead of an advisory panel meeting.

  • Schering-Plough and Merck Tuesday said U.S. regulators had accepted the marketing application for their experimental allergy drug, which combines two widely used existing treatments into a single tablet.